2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, S. A, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal Of Clinical Oncology 2019, 37: jco.18.01207. PMID: 30715997, PMCID: PMC6553812, DOI: 10.1200/jco.18.01207.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAminopyridinesAntineoplastic AgentsBrain NeoplasmsChemotherapy, AdjuvantDisease ProgressionEnzyme ActivationFemaleGlioblastomaHumansMaleMiddle AgedMorpholinesNeoadjuvant TherapyNeoplasm Recurrence, LocalPhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsProgression-Free SurvivalTime FactorsConceptsPhase II trialCohort 2Cohort 1PI3K pathwayTumor tissueII trialRecurrent glioblastomaBrain penetrationPan-PI3K inhibitor buparlisibPathway inhibitionPathway activationCommon grade 3K pathwayPrimary end pointGreater adverse eventsProgression-free survivalPI3K pathway inhibitionPI3K pathway activationPlasma drug levelsSingle-agent efficacySignificant brain penetrationPI3K inhibitorsMedian PFSOpen labelAdverse events
2012
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
Welch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-Oncology 2012, 14: 1304-1311. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterOlder patientsCancer CenterSurvival rateLower baseline creatinine clearanceMedian progression-free survivalTwo-year survival rateBaseline creatinine clearanceDeep brain involvementSignificant renal toxicityMedian overall survivalPrimary CNS lymphomaProgression-free survivalTertiary care centerHigh-dose MTXPredictors of survivalFifth treatment cycleOcular radiationAggressive therapyCNS lymphomaBrain involvementCreatinine clearanceMost patientsOverall survivalPCNSL patientsLimited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer
Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. The Breast Journal 2012, 18: 345-350. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.Peer-Reviewed Original ResearchConceptsBrain metastasesOverall survivalBreast cancerDiagnosis of BMIncidence of BMMedian age 53 yearsRisk of BMTriple-negative breast cancerActuarial median survivalLimited overall survivalAge 53 yearsGroup of patientsPatterns of recurrenceSingle-institution studyNegative breast cancerElectronic medical recordsBM diagnosisMedian survivalMetastatic diseaseEntire cohortRetrospective studyTherapeutic optionsInstitutional databaseMedical recordsModern therapy
2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. JAMA Neurology 2005, 62: 1595-1600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.Peer-Reviewed Original ResearchConceptsPrimary central nervous lymphomaPathophysiologic mechanismsPrimary central nervous system lymphomaMemorial Sloan-Kettering Cancer CenterTreatment-related toxic effectsCentral nervous system lymphomaDiffuse white matter diseaseAvailable autopsy dataProgressive subcortical dementiaMental status changesNervous system lymphomaDepartment of NeurologyWhite matter damagePotential risk factorsWhite matter diseaseFrontal-subcortical circuitsMicrovascular alterationsNeurologic deteriorationCumulative incidenceClinical courseImproved survivalRetrospective reviewSystem lymphomaClinical findingsSubcortical dementia